carbapenems has been researched along with cp 70429 in 2 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (cp 70429) | Trials (cp 70429) | Recent Studies (post-2010) (cp 70429) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 16 | 3 | 7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dartois, V; Dick, T; Negatu, DA; Zimmerman, MD | 1 |
| Bouvier, M; Le Terrier, C; Nordmann, P; Poirel, L | 1 |
2 other study(ies) available for carbapenems and cp 70429
| Article | Year |
|---|---|
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cefuroxime; Humans; Lactams; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium abscessus | 2022 |
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Escherichia coli; Meropenem; Microbial Sensitivity Tests | 2023 |